Proven skin clearance
Proven skin clearance
Clearance over time
Percentage of adults on ICOTYDE who saw at least 90% clearer skin
After 6 months (24 weeks), patients and healthcare providers knew that ICOTYDE was being used. This may have increased results. Results may vary.
Completely clear skin
in 2x as many adults vs another treatment at 24 weeks
In 2 clinical studies, more than 3 out of 10 adults taking ICOTYDE vs less than 2 out of 10 adults taking another psoriasis pill achieved 100% clear skin.
Results may vary.
Explore before-and-after photos
0 months
4 months (16 weeks)
6 months (24 weeks)
0 months
4 months (16 weeks)
6 months (24 weeks)
0 months
4 months (16 weeks)
6 months (24 weeks)
0 months
1 month (4 weeks)
4 months (16 weeks)
At 1 month (4 weeks) 15% of people with at least moderate scalp psoriasis had a clear or almost clear scalp. At 4 months (16 weeks) 66% of people with at least moderate scalp psoriasis had a clear or almost clear scalp.
Who was studied?
ICOTYDE was studied in 2 clinical studies, ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2, including 1505 adults
with moderate to severe plaque psoriasis.
How were these studies done?
People took ICOTYDE alone without the use of topical psoriasis treatments.
At start of study
People were randomly given
either a placebo, ICOTYDE, or
Sotyktu®
4 months (16 weeks) into study
Those who were given
a placebo
were switched to
ICOTYDE after
4 months (16 weeks)
6 months (24 weeks) into study
Those who were given
Sotyktu®
were switched to
ICOTYDE after
6 months
(24 weeks)
Patients were evaluated at different time points throughout the study. After 6 months (24 weeks), patients and healthcare providers knew that ICOTYDE was being used. This may have increased results.
A placebo is a treatment that looks like the study medicine but does not contain an active ingredient.
Who was studied?
ICOTYDE was studied in 2 clinical studies, ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2, including 1505 adults
with moderate to severe plaque psoriasis.
How were these studies done?
People took ICOTYDE alone without the use of topical psoriasis treatments.
At start of study
People were randomly given
either a placebo, ICOTYDE, or
Sotyktu®
4 months (16 weeks) into study
Those who were given
a placebo
were switched to
ICOTYDE after
4 months (16 weeks)
6 months (24 weeks) into study
Those who were given
Sotyktu®
were switched to
ICOTYDE after
6 months
(24 weeks)
Patients were evaluated at different time points throughout the study. After 6 months (24 weeks), patients and healthcare providers knew that ICOTYDE was being used. This may have increased results.
A placebo is a treatment that looks like the study medicine but does not contain an active ingredient.
Photos are of real patients. Images
are owned by Janssen Biotech, Inc.,
a Johnson & Johnson company, from a clinical study.
Individual results may vary.
0 months
4 months (16 weeks)
6 months (24 weeks)
0 months
4 months (16 weeks)
6 months (24 weeks)
0 months
4 months (16 weeks)
6 months (24 weeks)
0 months
1 month (4 weeks)
4 months (16 weeks)
At 1 month (4 weeks) 15% of people with at least moderate scalp psoriasis had a clear or almost clear scalp. At 4 months (16 weeks) 66% of people with at least moderate scalp psoriasis had a clear or almost clear scalp.
Clearer skin, even in
hard-to-treat areas
In a clinical study of people with plaque psoriasis* with at least moderate severity in hard-to-treat areas
Most people (nearly 6 out of 10) saw clear or almost clear skin at 4 months (16 weeks)
After 4 months (16 weeks), patients and healthcare providers knew that ICOTYDE was being used. This may have increased results.
Scalp clearance
*In this study, people had plaque psoriasis on at least 1% of their body surface area.
Results may vary.
In a clinical study of people with plaque psoriasis* with at least moderate severity in hard-to-treat areas
Most people (nearly 6 out of 10) saw clear or almost clear skin at 4 months (16 weeks)
After 4 months (16 weeks), patients and healthcare providers knew that ICOTYDE was being used. This may have increased results.
Genital clearance
*In this study, people had plaque psoriasis on at least 1% of their body surface area.
Results may vary.
Who was studied?
ICOTYDE was studied in another clinical study, ICONIC-TOTAL, including 311 people 12 and older with plaque psoriasis
affecting hard-to-treat areas with at least moderate severity like the scalp and genitals. In this study, people had plaque psoriasis on
at least 1% of their body surface area.
How was the study done?
People took ICOTYDE alone without the use of topical psoriasis treatments.
At start of study
Adolescents and adults were randomly
given either placebo or ICOTYDE
4 months (16 weeks) into study
Those who were given a
placebo
were switched
to ICOTYDE after
4 months (16 weeks)
Patients were evaluated at different time points throughout the study. After 4 months (16 weeks), patients and healthcare providers knew that ICOTYDE was being used. This may have increased results.
A placebo is a treatment that looks like the study medicine but does not contain an active ingredient.
People saw significant improvement in itch symptoms
Who was studied?
ICOTYDE was studied in another clinical study, ICONIC-TOTAL, including 311 people 12 and older with plaque psoriasis
affecting hard-to-treat areas with at least moderate severity like the scalp and genitals. In this study, people had plaque psoriasis on at least 1% of their body surface area.
How was the study done?
People took ICOTYDE alone without the use of topical psoriasis treatments.
At start of study
Adolescents and adults were randomly given either placebo or ICOTYDE
4 months (16 weeks) into study
Those who were given a placebo
were switched
to ICOTYDE after
4 months (16 weeks)
Patients were evaluated at different time points throughout the study. After 4 months (16 weeks),
patients and healthcare providers knew that ICOTYDE was being used. This may have increased results.
A placebo is a treatment that looks like the study medicine but does not contain an active ingredient.
Sotyktu is a registered trademark of Bristol-Myers Squibb Company.
